|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7704984||APIL||Extended estrogen dosing contraceptive regimen|| |
(5 years from now)
Lo Loestrin Fe is owned by Apil.
Lo Loestrin Fe contains Ethinyl Estradiol; Norethindrone Acetate.
Lo Loestrin Fe has a total of 1 drug patent out of which 0 drug patents have expired.
Lo Loestrin Fe was authorised for market use on 21 October, 2010.
Lo Loestrin Fe is available in tablet;oral dosage forms.
Lo Loestrin Fe can be used as lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
The generics of Lo Loestrin Fe are possible to be released after 02 February, 2029.
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic